Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery

To determine the safety of moderately hypofractionated radiation in the treatment of primary and locally recurrent RPS, based on the evaluation of acute radiation-related toxicity profile of each participant (30-day radiation toxicity)

Trial Details

NCT ID
NCT06812052
Phase
PHASE1
Sponsor
Brigham and Women's Hospital
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Radiation Therapy
  • Hypofractionationed Radiation Therapy
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Participants must have a histologically confirmed STS of the retroperitoneal space or infra-peritoneal spaces of pelvis
  • Participant must have radiologically measurable disease (RECIST 1.1), as confirmed by abdomino-pelvic CT or MRI
  • Participant must have primary, locally recurrent, or metastatic disease requiring treatment of the retroperitoneal mass
  • Tumor must be suitable for radiotherapy and surgery based on pre-treatment CT scan/MRI in multidisciplinary discussion with surgeon and radiation o…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →